As of Nov 19, 2026, 1 of 1 active firms rate MBRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MBRX EPS & revenue forecast
EPS · NEXT QUARTER
$-8.20
Range $-8.20 – $-8.20 · 1 analysts · -88% YoY
Next period, 1 analysts expect Moleculin Biotech Inc to earn $-8.20 a share (range $-8.20 – $-8.20), versus $-70.80 a year earlier. Full-year consensus is $-65.33, growing to $-23.40 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Moleculin Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MBRX.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$4.00-41.7% to target
Overall win rate
34%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #567
Buy
$4.00-41.7% to target
Overall win rate
30%
+ Follow
#3
Vernon Bernardino
HC Wainwright & Co. · Rank #582
Buy
$8.00+16.6% to target
Overall win rate
14%
+ Follow
#4
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$620.00+8937.9% to target
Overall win rate
28%
+ Follow
#5
SN
Sara Nik
HC Wainwright & Co.
Buy
$3.00-56.3% to target
Coverage
—
+ Follow
MBRX stock forecast FAQ
What is MBRX's average 12-month price target?+
The 1 active firms with a live target average $3.00 for Moleculin Biotech Inc over the next 12 months, ranging from a $3.00 high to a $3.00 low, as of Nov 19, 2026.
Is MBRX stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover MBRX?+
1 active firms have a recognized rating on Moleculin Biotech Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MBRX?+
Among analysts who currently cover MBRX, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #373). Their current call is Buy with a $4.00 target.
What is Moleculin Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $-8.20 per share (range $-8.20 – $-8.20) across 1 analysts. Full-year EPS is projected at $-65.33, rising to $-23.40 the following year.
How much revenue is Moleculin Biotech Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading MBRX lately?+
As of Nov 19, 2026, 1 of 1 active firms rate MBRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MBRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.